| Autor: |
Park MS; Program in Biomedical Science & Engineering, The Graduate School, Inha University, Incheon 22212, Korea., Kim SE; Program in Biomedical Science & Engineering, The Graduate School, Inha University, Incheon 22212, Korea., Lee P; Program in Biomedical Science & Engineering, The Graduate School, Inha University, Incheon 22212, Korea., Lee JH; College of Korean Medicine, Dongguk University, Goyang 10326, Korea., Jung KH; Department of Biomedical Sciences, College of Medicine, Inha University, Incheon 22332, Korea., Hong SS; Program in Biomedical Science & Engineering, The Graduate School, Inha University, Incheon 22212; Department of Biomedical Sciences, College of Medicine, Inha University, Incheon 22332, Korea. |
| Abstrakt: |
Angiopoietin-like 4 (ANGPTL4) has been identified as an adipokine involved in several non-metabolic and metabolic diseases, including angiogenesis, glucose homeostasis, and lipid metabolism. To date, the role of ANGPTL4 in cancer growth and progression, and metastasis, has been variable. Accumulating evidence suggests that proteolytic processing and posttranslational modifications of ANGPTL4 can significantly alter its function, and may contribute to the multiple and conflicting roles of ANGPTL4 in a tissue-dependent manner. With the growing interest in ANGPTL4 in cancer diagnosis and therapy, we aim to provide an up-to-date review of the implications of ANGPTL4 as a biomarker/oncogene in cancer metabolism, metastasis, and the tumor microenvironment (TME). In cancer cells, ANGPTL4 plays an important role in regulating metabolism by altering intracellular glucose, lipid, and amino acid metabolism. We also highlight the knowledge gaps and future prospect of ANGPTL4 in lymphatic metastasis and perineural invasion through various signaling pathways, underscoring its importance in cancer progression and prognosis. Through this review, a better understanding of the role of ANGPTL4 in cancer progression within the TME will provide new insights into other aspects of tumorigenesis and the potential therapeutic value of ANGPTL4. [BMB Reports 2024; 57(8): 343-351]. |
